Key result
Beta-blocker uptitration after M-TEER linked to ~45% lower all-cause mortality in secondary MR.
Why the study?
Optimal medical therapy for patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair remains unclear.
Does beta-blocker uptitration reduce mortality in patients after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation?
Cohort (n=1,474)
Yes
Does beta-blocker uptitration reduce mortality in patients after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation?
Beta-blocker uptitration after M-TEER for secondary mitral regurgitation is associated with reduced all-cause and cardiovascular mortality at 2 years, particularly in patients with LVEF ≤40%.
Answers are grounded in this paper and cite their sources.
Beta-blocker uptitration was associated with lower mortality after M-TEER for SMR; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: Optimal medical therapy for patients with secondary mitral regurgitation (SMR) undergoing transcatheter edge-to-edge mitral valve repair (M-TEER) remains unclear. This study aimed to investigate the association between beta-blocker uptitration and clinical outcomes after M-TEER. METHODS: Using data from the Japanese multicenter registry, we examined 1474 patients who underwent M-TEER for SMR between April 2018 and June 2021. Beta-blocker uptitration was defined as an increased dose of beta-blockers 1 month after M-TEER compared with that before M-TEER. The 2-year clinical outcomes were compared between patients with and without beta-blocker uptitration, utilizing multivariable Cox regression analyses and propensity score matching (PSM). RESULTS: Of the 1474 patients who underwent M-TEER, 272 (18.4 %) were receiving increasing doses of beta-blockers at the 1-month follow-up. These patients had lower left ventricular ejection fraction (LVEF) and higher B-type natriuretic peptide levels. Most patients in the beta-blocker uptitration group received less than the target dose of beta-blockers. Multivariable Cox regression analyses showed that beta-blocker uptitration was significantly associated with a lower risk of all-cause (adjusted hazard ratio [HR]: 0.55; 95 % confidence interval [CI]: 0.36-0.84; P = 0.006) and cardiovascular mortalities (adjusted HR: 0.45, 95 % CI: 0.26-0.79, P = 0.006). PSM analyses revealed consistent findings. Subgroup analyses revealed a significant interaction between beta-blocker uptitration and LVEF≤40 % (interaction P = 0.018). CONCLUSIONS: In patients with SMR, beta-blocker uptitration after M-TEER was associated with better clinical outcomes, especially in the group with an LVEF≤40 %. Efforts to uptitrate guideline-directed medical therapy after M-TEER for SMR may be necessary, even if reaching the target dose proves challenging.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2024) conducted a cohort in Secondary mitral regurgitation (SMR) (n=1,474). Beta-blocker uptitration vs. No beta-blocker uptitration was evaluated on All-cause mortality (HR 0.55, 95% CI 0.36-0.84, p=0.006). Beta-blocker uptitration after M-TEER for secondary mitral regurgitation was associated with a lower risk of all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: